ORMP Key Stats
Street Insider07/23 15:32
Street Insider07/01 09:13
PR Newswire06/10 08:15
PR Newswire05/29 12:00
ORMP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oramed Pharmaceuticals is up 10.51% over the last year vs S&P 500 Total Return up 16.61%, Galmed Pharmaceuticals up N/A, and Evogene up 14.78%.
Balance Sheet View Statement
Y-Ratings for ORMP
Portfolio Strategies Featuring ORMP
Did Oramed Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Company Website: http://www.oramed.com
- IR Website: http://ir.oramed.com/phoenix.zhtml?c=180902&p=irol-irhome
- HQ Country: Israel
- HQ State/Province: N/A
- Incorporation Country: United States
- Incorporation State/Province: Delaware
- Est. Current Fiscal Quarter End: May 31, 2014
- Est. Current Fiscal Year End: August 31, 2014
- Last Fiscal Quarter End: May 31, 2013
- Last Fiscal Year End: August 31, 2012
- NAICS: Pharmaceutical Preparation Manufacturing
- NAICS Code: 325412
- NAICS Industry: Pharmaceutical and Medicine Manufacturing
- NAICS Sector: Manufacturing
Oramed Pharmaceuticals is a pharmaceutical company. It is engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.
ORMP Excel Add-In Codes
- Name: =YCI("ORMP","name")
- Description: =YCI("ORMP","description")
- Sector: =YCI("ORMP","sector")
- Industry: =YCI("ORMP","industry")
- Est. Current Fiscal Year End: =YCI("ORMP","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.